The absence of evidence-based guidelines for prostate cancer treatment led the Institute of Medicine to include localized prostate cancer treatment among the 25 most important topics for comparative effectiveness research.
T he most critical problem facing prostate cancer patients and their physicians is uncertainty about how to manage the disease. The absence of evidence-based guidelines for prostate cancer treatment led the Institute of Medicine to include localized prostate cancer treatment among the 25 most important topics for comparative effectiveness research. 1 The premise of comparative effectiveness research is to "inform health care decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options." 2 The emphasis on comparative effectiveness in medicine gave rise to patient-centered outcomes research that seeks to tailor care to a patient's personal characteristics, conditions, and preferences. 3 Central to clinical decision making in prostate cancer treatment is whether to screen and to treat men, given their life expectancy, presence of comorbid conditions, and potential outcomes.
For the past 2 decades, a large body of literature has focused on shared decision making in prostate cancer treatment, 4 overtreatment of men with low-risk disease, 5 and the cost of prostate cancer treatment, contrasted with its tenuous benefits. 6 At the crux of this research is whether the potential benefits of one type of treatment (eg, surgery) are greater than the benefits from another type of treatment (eg, radiation), or if any treatment is better than no treatment as most patients do not die from prostate cancer and instead have other chronic conditions that lead to death. Moreover, it is unclear how other chronic conditions affect the decision to screen or once diagnosed, the selection of treatment options, [7] [8] [9] including the use of newer, expensive forms of radiation treatment versus active surveillance. 10 Prostate cancer treatment may exacerbate comorbid conditions and, likewise, some comorbid conditions may worsen prostate cancer treatment outcomes. Androgen deprivation therapy (ADT), for example, has been associated with increased risk of sudden cardiac death in men with coronary artery disease. [11] [12] [13] [14] Men with comorbid conditions have higher all-cause mortality, 8 but whether mortality is hastened or delayed by prostate cancer treatment is unknown.
Using a population-based sample, we compare prostate cancer treatment in men with and without prevalent comorbid conditions. We examine whether treatment influences all-cause and cancer-specific mortality by comparing treated and untreated men with comorbid conditions. The chronic conditions investigated are: diabetes, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), and cerebrovascular disease (CVA). These conditions were selected because of their high prevalence in the population. The study sample comprised men aged 66 years and older. Findings from this study have implications for clinical management of prostate cancer in older men with comorbid conditions and fits within a framework of comparative effectiveness and patientcentered approaches to care.
METHODS

Data
We used the linked SEER-Medicare data from 2004 to 2009. The SEER program is funded by the National Cancer Institute and covers approximately 28% of the US population. 15 Incident cases are available from 2009 with claims to 2010; and survival is reported through December 2011. A total of 172,836 incident prostate cancer cases in men aged 66 years and older were in the dataset.
To ensure we identified men that were likely to have favorable survival (and thus have the potential to benefit from treatment) and complete data, we applied the following exclusions to the sample: prior cancer diagnosis (n = 6135); unstaged cancer (n = 10,006); histology other than adenocarcinoma (n = 5043) or metastatic disease (4928); identification through a death certificate or autopsy (n = 26); and not enrolled in fee-for-service Medicare parts A and B (n = 15,335) or enrolled in a managed care plan (38,007). Another 970 men were excluded because their month of diagnosis was unknown and, therefore, we could not assess their observation period. We excluded patients with the Charlson comorbid conditions other than those of interest (n = 4889) and 13,934 additional men because they had insufficient information to assign them to a risk category. Following these exclusions, the analytic sample comprised 73,563 men.
Identification of Comorbid Conditions
We used the Deyo et al 16 18 which has been used to explain the probability and extent of cancer treatment. 17, 19 We used all inpatient, outpatient, and physician claims for services rendered in the year before diagnosis to identify comorbid conditions (see Appendix for codes). The "healthy" group was conservatively defined as those patients who did not have any of the 12 Charlson comorbid conditions. 18
Identification of Treatment Type
Treatment type was identified from the inpatient, outpatient, and physician claim files. Treatments included the following mutually exclusive groups: radical prostatectomy, radiation (including intensity modulated radiation therapy, brachytherapy, and conformal and proton therapies), ADT alone or in combination with radiation, and a single category for combinations of ADT with radical prostatectomy or radical prostatectomy with radiation. Other treatments that are not definitive cancer treatment like suprapubic, retropubic, perineal, or transurethral resection of the prostate were not considered as cancer treatments (< 2% of the sample). We excluded patients who received these treatments from the sample in a sensitivity analysis and found that the results were unchanged. All treatments occurring within 1 year following diagnosis were considered cancer-directed. Codes used to identify treatments are included in the Appendix.
Survival
Survival time was defined as the number of months from the month of diagnosis to the month of death. The survival time for patients who were still alive was censored and calculated from the month of diagnosis to December 31, 2011. All-cause and cancer-specific mortality was used in the survival analysis.
Control Variables
Age was grouped into the following categories: 66-74 years, 75-79 years, and 80 years and older. Race was categorized as white, African American, other, or unknown. The sample included 1564 Hispanic men (< 2% of the sample). Once we stratified the sample by risk, treatment, and comorbidity, the Hispanic sample was too small to extract meaningful results and, therefore, we included these men in the "other" race group. Marital status was defined as married, previously married, not married, and unknown. We also included variables for the SEER region in which men resided and the year of diagnosis. In a separate analysis (results not shown), we controlled for census tract education and median household income. The sample was reduced by 368 observations with missing data. The results were unchanged with the addition of these variables and the loss of observations.
We assigned men a risk level using the National Comprehensive Cancer Network (NCCN) guidelines, wherein high-risk patients is defined as T3-T4, or Gleason score 8-10, or PSA >20, or any T, N1; intermediate-risk patients was defined as T2b-T2c, or Gleason score 7, or PSA 10-20; and low-risk patients were T1-T2a, or Gleason score r6, or PSA <10. 20
Statistical Analysis
We described patients by comorbidity type. Statistically significant differences in categorical variables were determined by the Pearson w 2 test and the t test was used to determine statistically significant differences between continuous variables. The sample was then stratified by risk level. Separate adjusted logistic regression models were used to measure the relationship between the independent variables and receipt of treatment, by treatment type, and an inclusive category designated as "any treatment." We reported odds ratios (OR), 95% confidence intervals (CI), and Pvalues. P-values were derived from likelihood ratio tests and are 2-sided. Statistical significance was determined as P < 0.05.
We used a competing risks regression model to estimate survival, controlling for whether the patient received cancer-directed treatment. Failure was defined as prostate cancer mortality and the competing event as noncancer mortality. Estimates are reported as hazard ratios (HR) with 95% CI. If treated men were in better health than those who were not treated, the survival analysis would incorrectly favor treatment. Therefore, a propensity score was estimated using the logistic regression model predicting receipt of treatment. 21 In addition to demographic variables, we used a wide range of variables to estimate the propensity of receiving a treatment. We included variables for the use of canes or wheelchairs and oxygen tanks using claims from the Durable Medical Equipment file. We calculated the number of inpatient admissions, total charges, and length of stays for each patient in the year before treatment. We also calculated the number of outpatient visits and their total charges for each patient. We created dummy variables for several conditions that were present before treatment that might affect the decision to treat. These conditions included coronary arterial disease, chronic renal disease, chronic hepatitis, depression, psychosis, dementia, obesity, loss of special senses, or conditions that might be related to the tumor-like bladder neck obstruction, frequent urination, hematuria, prostatitis, and urine infections. We used all these variables to estimate the propensity scores.
We used nearest neighbor, the kernel, and the caliper methods with and without replacement algorithms to match the treated sample to the nontreated patients. We tested the balance of covariates between the 2 groups using the standardized differences. The best balance was achieved using the caliper (0.1) method without replacement. All covariates had <10% bias between the 2 groups. We used the matched samples in the survival analysis. However, because this method reduced the sample size to 36,302 observations, we compared the results to 2 other models: the first used the propensity score as a regressor and the second accounted for the treatment choice by including the inverse probability weights in the regression models. Data management, descriptive statistics, and logistic regression models were conducted using SAS, version 9.3. 22 Propensity score matching and competing risk regression models were conducted using STATA12. Table 1 reports the sample characteristics by each comorbid condition. Nearly half of the men had Z1 of the comorbid conditions of interest (46%). The most common comorbid condition was diabetes mellitus (19%) and a substantial share had multiple comorbid conditions (11%). Men with CHF, CVA, and multiple comorbid conditions were older than men without comorbid conditions, whereas men with diabetes were younger. There were a higher proportion of African Americans and unmarried men among those with comorbidities relative to those without comorbid conditions.
RESULTS
Descriptive Statistics
Over half of all men received cancer-directed treatment, irrespective of comorbid condition. Men with diabetes were more likely to receive cancer-directed treatment than men without comorbidities, whereas men with CHF or multiple comorbid conditions were least likely to be treated. Among those treated, men were most likely to receive radiation alone or ADT and radiation together.
About a fifth of the men died during the study period and most deaths were from causes other than prostate cancer. The highest rates of death were among men with CHF or those with multiple comorbid conditions. The median time until death was approximately 3 years for all-cause mortality, whereas the approximate median time until a prostate cancer death was a little more than 2 years from diagnosis. Across all conditions, men were much more likely to die compared with men without comorbidities.
Treatment Table 2 reports the odds ratios from adjusted logistic regressions that predict the likelihood of treatment. Men who had CHF or multiple comorbid conditions were less likely to be treated than men without comorbid conditions (OR = 0.77; 95% CI, 0.69-0.86; and OR = 0.77; 95% CI, 0.73-0.82, respectively), whereas men with diabetes were more likely to be treated (OR = 1.14; 95% CI, 1.09-1.20). Men with comorbid conditions were less likely to have a radical prostatectomy as men without comorbidities. In contrast, the likelihood of being treated with radiation alone was higher for men with COPD (OR = 1.14; 95% CI, 1.07-1.22), CVA (OR = 1.13; 95% CI, 1.03-1.24), and diabetes (OR = 1.13; 95% CI, 1.07-1.18) and, across all comorbid conditions (including multiple conditions), men were more likely to have ADT and radiation together than men without these conditions.
When the sample was stratified by risk level, the patterns observed for the full sample remained consistent but, in some cases, lose statistical significance, suggesting that few differences in treatment patterns exist between men with and without comorbid conditions within risk group. Alternatively, statistical significance may be reduced due to the sample becoming noticeably smaller in some risk and treatment groups. The likelihood of radical prostatectomy remained lower among men with comorbidities and the likelihood of receiving ADT and radiation was higher among men with comorbid conditions relative to men without comorbid conditions (statistically significant ORs range from 1.15 to 1.38). Figure 1 depicts the percent of deaths that are cancer and noncancer related by comorbid condition and risk level within 3 years of diagnosis (N = 64,989). Men with high-risk prostate cancer have higher rates of death from prostate cancer, although prostate cancer deaths comprise a small proportion of total deaths, even among high-risk patients. Very few patients with low-risk disease die from prostate cancer or other causes. Men with CHF or multiple conditions have the highest death rates, whereas men with diabetes or no comorbid conditions have the lowest death rates. Table 3 reports the hazard ratios of prostate cancer mortality versus other causes for treated men stratified by risk level and comorbid condition. Across the 3 methods used to handle propensity scores, HRs were similar. Among men with low-risk disease and comorbid conditions, treatment offered no survival benefit except for CHF patients (HR = 0.24; 95% CI, 0.09-0.64; caliper matching method). A survival benefit is observed for men with intermediate-risk disease and COPD (HR = 0.70; 95% CI, 0.51-0.95) and multiple comorbid conditions (HR = 0.46; 95% CI, 0.35-0.61) using the matched sample. However, statistically significant differences in survival were observed for men with other conditions when we used the propensity score as an inverse probability weight or as a regressor. All men with high-risk disease, with or without comorbid conditions, experienced a survival benefit from treatment; with ratios ranging from 0.45 for those with no comorbid conditions to 0.69 for CVA patients (P < 0.05). We note that when we stratify by risk level, the samples become smaller, leading to wider confidence intervals and possible loss of statistical significance. Overall, the results suggest a survival benefit for men with intermediate-risk and high-risk disease, irrespective of comorbid conditions.
Mortality
CONCLUSIONS
Prostate cancer is the most common form of nonskin cancer in men in the United States. Annually, an estimated 200,000 men will be diagnosed with prostate cancer and approximately 30,000 will die from the disease. 23 The Agency for Healthcare Research and Quality, Department of Health and Human Services, and others have joined the Institute of Medicine's call for comparative effectiveness research of 1, 23, 24 Our study provides evidence about the role of prevalent comorbid conditions in treatment decisions and subsequent survival for a population-based sample of men diagnosed with prostate cancer. This evidence can be used in comparative effectiveness studies and patientcentered decision making for screening and treatment. Although nearly half of the sample had at least one of the conditions of interest, the evidence suggests that comorbid conditions do not appear to enter the decision about whether to treat unless the patient is diagnosed with CHF or has multiple comorbid conditions in which case treatment is less likely. Similar findings have been reported in a sample of men aged 75 years and older with low-risk disease. 25 Moreover, men with diabetes are more likely to be treated compared with men without comorbid conditions. Radiation alone or ADT in addition to radiation are the predominant treatments for men with comorbid conditions. Other research, in addition to our own, established that comorbidities lead to higher mortality in cancer patients. 8, [26] [27] [28] [29] [30] [31] Patients with diabetes, es-pecially those with low-risk disease, are just as unlikely to benefit from treatment as men with other comorbid conditions, a fact that may be underappreciated by physicians.
Our analysis of data from a population-based sample finds no survival benefit for men with low-risk disease and comorbid conditions with the exception of men with CHF. Taken together, the evidence suggests caution when recommending treatment for men with prostate cancer and comorbid conditions, particularly those with low-risk disease. As many as 20%-30% of older men nationwide have prevalent comorbidities severe enough to influence modification of cancer treatment. 32 Consideration toward comorbid conditions could also enter into the prostate cancer screening decision so that men with these conditions are not screened and potentially exposed to harm arising from the diagnosis and treatment of low-risk disease.
The decision to treat men with comorbidities may be driven by the perception that radiation, with or without androgen deprivation, is safer than radical prostatectomy and, thus, may (2004) (2005) (2006) (2007) (2008) (2009) ). The samples for radical prostatectomy, radiation only, and ADT plus radiation do not sum to the sample size reported for "any treatment" because of the omission of men who received RP with ADT or RP with radiation. There were 34, 461, and 462 men in low-risk, intermediate-risk, and high-risk categories, respectively, who received these treatments.
ADT indicates androgen deprivation therapy; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular disease; OR, odds ratio; RP, radical prostatectomy. ***P < 0.01. **P < 0.05.
be more appropriate to offer to men who are not surgical candidates. However, the evidence suggests otherwise. Recent publications indicate that comorbid conditions, such as diabetes and coronary artery disease, make it less likely that men will benefit from radiation therapy. 33, 34 As this information becomes disseminated throughout the radiation oncology community, it is hoped that fewer men with these comorbidities will be unnecessarily treated. Men may also benefit from participation in multidisciplinary clinics wherein active surveillance is recommended more often for low-risk patients. 35 The study has 5 limitations. First, detailed clinical information such as biochemical progression or performance status is not included in SEER-Medicare data. Nonetheless, SEER-Medicare data remain the best and largest, populationbased data available for assessing treatment and survival for men with prostate cancer and is ideal for comparative effectiveness analyses that consider conditions specific to the patient in general practice settings. Second, SEER-Medicare data are specific for men aged 65 years and older and the fee-forservice population. Therefore, the findings may not be generalized to younger men or to men who are enrolled in managed care insurance plans. Third, prostate cancer as the cause of death may be underreported. Newschaffer et al 36 reported that men treated initially with surgery or radiation were more likely to have death attributed to other cancers than men treated less aggressively. Older age at diagnosis also correlates inversely with the likelihood of attributing cause of death to prostate cancer. 36, 37 Fourth, the length of follow-up in this patient population is relatively short. Prostate cancer, even in its highgrade form, generally is a disease with a long natural history. Thus, with additional follow-up, it may be shown that certain populations of patients will benefit from treatment. Finally, when we stratify by comorbid condition and risk level, the sample sizes become smaller, which may affect the statistical significance of coefficients. Comorbid conditions were prevalent in the sample of men with prostate cancer. Overall, men with comorbid conditions, with the exception of CHF or multiple conditions, were as likely or more likely to receive cancer-directed treatment for prostate cancer as men without comorbid conditions. Men with comorbid conditions were more likely to be treated with radiation alone or in combination with ADT. Survival benefits are questionable in most men with low-risk disease. In a patient-centered approach toward care, men and their treating physicians need a better understanding of treatment outcomes given the presence of comorbid conditions. With this information, harms and benefits associated with treatment can be better weighed, along with the initial decision to screen, in the context of the patient's overall health.
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